Europe In Focus
St Patrick’s Day is a big deal in the US – it’s used as an excuse to drink Guinness, wear copious amounts of emerald and carry a plastic shillelagh. Oh, and dye rivers and waterways Kelly green.
And so with this in mind, the captains of Irish industry held a charm offensive at the New York Stock Exchange, as close to St Paddy’s day as it’s safe to get in NYC without suffering a hangover.
What does 2011 hold in store for the pharma industry and where does Ireland fit in?
Dave Shanahan: It’s going to be challenging. The industry is struggling due to the lack of new chemical entities, US healthcare reform, a lack of blockbuster products, big losses in patent protected revenues and market share losses to generics. The hurdles companies have to go through today to secure marketing authorization are enormous. Many products on the market today would not pass the threshold that regulators are now imposing. Ireland’s competitiveness has greatly improved with a decrease in operating costs. Our multi-national exports are performing very strongly.
industry includes working with Johnson&Johnson, ICI, AstraZeneca and Pfizer.
To many the Channel Islands seen as inter-changeable or a single jurisdiction. The truth is that while both jurisdictions have similar laws and legal traditions that make each an ideal destination for global businesses and HNW individuals, it’s the differences between each island that makes the Channel Islands especially attractive. At Collas Crill we understand that the whole is greater than the sum of the parts. Being able to offer global clients a quality Channel Islands product, with the choice of Guernsey or Jersey niches to suit specific needs, makes an already good proposition look even better.
More Articles...
